Bioventus (BVS) Cash & Current Investments (2020 - 2026)

Bioventus has reported Cash & Current Investments for 7 years, with the latest figure at $35.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 57.21% year-over-year to $35.8 million; the trailing twelve-month figure through Mar 2026 stood at $35.8 million (up 57.21% YoY), and the FY2025 full-year result was $51.2 million, up 23.22% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $35.8 million, down from $51.2 million in the prior quarter.
• The five-year high for Cash & Current Investments was $51.2 million in Q4 2025, with the low at $22.8 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $35.6 million across 5 years, with a median of $34.4 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 75.75% — and 2024, when it surged 60.56%.
• Bioventus' Cash & Current Investments stood at $30.2 million in 2022, then gained by 22.36% to $37.0 million in 2023, then advanced by 12.49% to $41.6 million in 2024, then climbed by 23.22% to $51.2 million in 2025, then tumbled by 30.04% to $35.8 million in 2026.
• The last three Cash & Current Investments figures came in at $35.8 million (Q1 2026), $51.2 million (Q4 2025), and $42.2 million (Q3 2025), per Business Quant data.